title: How does TPF improve survival over PF?
authors.forename: Yoann
authors.initials: Y
authors.lastname: Pointreau
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Atean
authors.forename: Gilles
authors.initials: G
authors.lastname: Calais
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality*; D002945:Cisplatin / Q000008:administration & dosage; D015986:Confounding Factors, Epidemiologic; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D000077143:Docetaxel; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D059012:Lost to Follow-Up; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012107:Research Design / Q000592:standards*; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil